Literature DB >> 22075205

Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action.

Pál Gyombolai1, Dorottya Pap, Gábor Turu, Kevin J Catt, György Bagdy, László Hunyady.   

Abstract

In the past years, the relationship between the endocannabinoid system (ECS) and other hormonal and neuromodulatory systems has been intensively studied. G protein-coupled receptors (GPCRs) can stimulate endocannabinoid (eCB) production via activation of G(q/11) proteins and, in some cases, G(s) proteins. In this review, we summarize the pathways through which GPCR activation can trigger eCB release, as well as the best known examples of this process throughout the body tissues. Angiotensin II-induced activation of AT(1) receptors, similar to other G(q/11)-coupled receptors, can lead to the formation of 2-arachidonoylglycerol (2-AG), an important eCB. The importance of eCB formation in angiotensin II action is supported by the finding that the hypertensive effect of angiotensin II, injected directly into the hypothalamic paraventricular nucleus of anaesthetized rats, can be abolished by AM251, an inverse agonist of CB(1) cannabinoid receptors (CB(1)Rs). We conclude that activation of the ECS should be considered as a general consequence of the stimulation of G(q/11)-coupled receptors, and may mediate some of the physiological effects of GPCRs. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075205      PMCID: PMC4169275          DOI: 10.1016/j.mce.2011.10.011

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  89 in total

1.  Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus.

Authors:  N Varma; G C Carlson; C Ledent; B E Alger
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells.

Authors:  E V Berdyshev; P C Schmid; R J Krebsbach; H H Schmid
Journal:  FASEB J       Date:  2001-10       Impact factor: 5.191

3.  Cooperative endocannabinoid production by neuronal depolarization and group I metabotropic glutamate receptor activation.

Authors:  Takako Ohno-Shosaku; Jumpei Shosaku; Hiroshi Tsubokawa; Masanobu Kano
Journal:  Eur J Neurosci       Date:  2002-03       Impact factor: 3.386

4.  Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors.

Authors:  T Maejima; K Hashimoto; T Yoshida; A Aiba; M Kano
Journal:  Neuron       Date:  2001-08-16       Impact factor: 17.173

5.  Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus.

Authors:  Jimok Kim; Masako Isokawa; Catherine Ledent; Bradley E Alger
Journal:  J Neurosci       Date:  2002-12-01       Impact factor: 6.167

6.  Enhanced response of subfornical organ neurons projecting to the hypothalamic paraventricular nucleus to angiotensin II in spontaneously hypertensive rats.

Authors:  Hiroko Miyakubo; Yasushi Hayashi; Junichi Tanaka
Journal:  Auton Neurosci       Date:  2002-01-10       Impact factor: 3.145

Review 7.  Endocannabinoid signaling in the brain.

Authors:  Rachel I Wilson; Roger A Nicoll
Journal:  Science       Date:  2002-04-26       Impact factor: 47.728

8.  Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism.

Authors:  Shi Di; Renato Malcher-Lopes; Katalin Cs Halmos; Jeffrey G Tasker
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

Review 9.  Cardiovascular effects of cannabinoids.

Authors:  Michael D Randall; David Harris; David A Kendall; Vera Ralevic
Journal:  Pharmacol Ther       Date:  2002-08       Impact factor: 12.310

10.  The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure.

Authors:  Zhi-Hua Zhang; Joseph Francis; Robert M Weiss; Robert B Felder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-07       Impact factor: 4.733

View more
  20 in total

1.  Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy.

Authors:  Mohanraj Rajesh; Sándor Bátkai; Malek Kechrid; Partha Mukhopadhyay; Wen-Shin Lee; Béla Horváth; Eileen Holovac; Resat Cinar; Lucas Liaudet; Ken Mackie; György Haskó; Pál Pacher
Journal:  Diabetes       Date:  2012-02-07       Impact factor: 9.461

Review 2.  Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists.

Authors:  E Kirilly; L Hunyady; G Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2012-09-19       Impact factor: 3.575

3.  Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators.

Authors:  Samantha E Yohn; Daniel J Foster; Dan P Covey; Mark S Moehle; Jordan Galbraith; Pedro M Garcia-Barrantes; Hyekyung P Cho; Michael Bubser; Anna L Blobaum; Max E Joffe; Joseph F Cheer; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  Mol Psychiatry       Date:  2018-08-16       Impact factor: 15.992

4.  Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors.

Authors:  Mária Szekeres; György L Nádasy; Gábor Turu; Eszter Soltész-Katona; Zsuzsanna E Tóth; András Balla; Kevin J Catt; László Hunyady
Journal:  J Biol Chem       Date:  2012-07-11       Impact factor: 5.157

5.  Ultrastructural evidence for synaptic contacts between cortical noradrenergic afferents and endocannabinoid-synthesizing post-synaptic neurons.

Authors:  B A S Reyes; N A Heldt; K Mackie; E J Van Bockstaele
Journal:  Neuroscience       Date:  2015-07-08       Impact factor: 3.590

6.  Presynaptic mGluRs Control the Duration of Endocannabinoid-Mediated DSI.

Authors:  Phillip L W Colmers; Jaideep S Bains
Journal:  J Neurosci       Date:  2018-10-24       Impact factor: 6.167

7.  Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system.

Authors:  Keith A Sharkey; Nissar A Darmani; Linda A Parker
Journal:  Eur J Pharmacol       Date:  2013-11-01       Impact factor: 4.432

Review 8.  Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.

Authors:  Myriam Dao; Helene François
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-07       Impact factor: 5.555

9.  Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats.

Authors:  Chris L Schaich; Hossam A Shaltout; K Bridget Brosnihan; Allyn C Howlett; Debra I Diz
Journal:  Physiol Rep       Date:  2014-08-28

10.  CB1 receptor activation in the rat paraventricular nucleus induces bi-directional cardiovascular effects via modification of glutamatergic and GABAergic neurotransmission.

Authors:  Emilia Grzęda; Eberhard Schlicker; Marek Toczek; Iwona Zalewska; Marta Baranowska-Kuczko; Barbara Malinowska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-22       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.